The Role of MRAs in the Management of HF-Distinguishing nsMRAs from traditional sMRAs_Benefits, Challenges & Clinical Trial Data

Distinguishing nsMRAs from traditional sMRAs_Benefits, Challenges & Clinical Trial Data

Video Transcription

Video Summary

Pharmacist Tara Schreck explains differences between steroidal and non-steroidal mineralocorticoid receptor antagonists (MRAs) like spironolactone, aplerenone, and finerenone. Steroidal MRAs have steroid rings, less selectivity, and more off-target hormone effects. Non-steroidal finerenone is highly selective with fewer side effects and shorter half-life. All three reduce inflammation and fibrosis, benefiting heart and kidney diseases. Clinical trials show finerenone reduces cardiovascular events and chronic kidney disease progression, especially in diabetes patients, with lower hyperkalemia risk. Challenges include newer drug status, cost, limited real-world data, and need for more head-to-head comparisons and studies with SGLT2 inhibitors.

Keywords

steroidal mineralocorticoid receptor antagonists

non-steroidal mineralocorticoid receptor antagonists

finerenone

cardiovascular and kidney disease

clinical trials